https://www.insurerbrain.com/w/index.php?action=history&feed=atom&title=Definition%3ADepartment_of_Justice_%28DOJ%29_antitrust_reviewDefinition:Department of Justice (DOJ) antitrust review - Revision history2026-04-29T07:37:55ZRevision history for this page on the wikiMediaWiki 1.43.8https://www.insurerbrain.com/w/index.php?title=Definition:Department_of_Justice_(DOJ)_antitrust_review&diff=10156&oldid=prevPlumBot: Bot: Creating new article from JSON2026-03-11T06:58:24Z<p>Bot: Creating new article from JSON</p>
<p><b>New page</b></p><div>⚖️ '''Department of Justice (DOJ) antitrust review''' is the federal scrutiny applied by the DOJ's Antitrust Division to mergers, acquisitions, and other consolidation activity that could harm competition — a process that routinely touches the insurance industry when large [[Definition:Insurance carrier | carriers]], [[Definition:Reinsurance | reinsurers]], [[Definition:Insurance broker | brokerage houses]], or [[Definition:Insurtech | insurtech]] platforms combine. The DOJ shares merger-review authority with the [[Definition:Federal Trade Commission (FTC) review | FTC]] under the [[Definition:Hart-Scott-Rodino Act | Hart-Scott-Rodino Act]], and the two agencies allocate cases between themselves based on sector familiarity and historical precedent.<br />
<br />
⚙️ After receiving an HSR filing, the DOJ evaluates whether the proposed transaction would substantially lessen competition in any well-defined market. For insurance, that analysis can involve mapping [[Definition:Market concentration (insurance) | market concentration]] across [[Definition:Line of business | lines of business]], distribution tiers, and state-by-state geographies — often relying on [[Definition:National Association of Insurance Commissioners (NAIC) | NAIC]] data, [[Definition:Annual statement | statutory filings]], and [[Definition:Premium | premium]]-volume statistics. Should concerns emerge, the Division may issue civil investigative demands, negotiate a [[Definition:Competitive impact statement | competitive impact statement]] and consent decree requiring [[Definition:Divestiture | divestitures]] or conduct remedies, or — in extreme cases — file suit to block the deal entirely. A notable feature of DOJ review for insurance transactions is that it runs in parallel with, and does not preempt, the separate approval requirements imposed by [[Definition:State insurance department | state insurance regulators]] under [[Definition:Insurance holding company act | insurance holding-company acts]].<br />
<br />
💡 The practical implication for insurance dealmakers is that federal antitrust clearance and state regulatory approval form a dual-track gauntlet, each with its own timeline, information demands, and remedial toolkit. Deals involving [[Definition:Cross-border M&A (insurance) | cross-border elements]] add a third layer of international competition review. Sophisticated acquirers build antitrust risk assessments into their deal models from the outset, stress-testing which product-market combinations might trigger a second request and quantifying the value at risk if [[Definition:Book of business | books of business]] or operational units must be divested to satisfy the DOJ.<br />
<br />
'''Related concepts:'''<br />
{{Div col|colwidth=20em}}<br />
* [[Definition:Federal Trade Commission (FTC) review]]<br />
* [[Definition:Competitive impact statement]]<br />
* [[Definition:Hart-Scott-Rodino Act]]<br />
* [[Definition:Market concentration (insurance)]]<br />
* [[Definition:Herfindahl-Hirschman Index (HHI)]]<br />
* [[Definition:Multi-state regulatory approval]]<br />
{{Div col end}}</div>PlumBot